Real-world data on benralizumab for severe asthma: what happens outside clinical trials?
NCT ID NCT07218172
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks back at medical records of 197 adults in Israel who started benralizumab for severe asthma between 2019 and 2024. Researchers will count how many asthma attacks (exacerbations) patients had before and after starting the drug. The goal is to see how well benralizumab works in everyday practice, not just in controlled studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- benralizumab
- What this could lead to
- If successful, this study could provide real-world evidence on how well benralizumab controls severe asthma in routine practice.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by other factors and cannot prove cause and effect.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Tel Aviv, Israel
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single injection tame severe asthma in fungal allergy?
- Could a simple exercise programme boost asthma remission?
- A two-step strategy: biologic drug may pave the way for immunotherapy in severe olive pollen asthma
- Could a biologic drug free severe asthma patients from High-Dose steroids?
- Beyond breathing: could an asthma drug lift emotional burdens for patients and partners?
- Scientists probe why tezepelumab doesn't stop all asthma attacks